{"doi":"10.1089/ars.2023.0241","title":"Nicotinamide Adenine Dinucleotide (NAD <sup>+</sup> )-Dependent Signaling in Neurological Disorders","abstract":"Significance: Nicotinamide adenine dinucleotide (NAD + ) participates in redox reactions and NAD + -dependent signaling processes, which couples the enzymatic degradation of NAD + to posttranslational modifications of proteins or the production of second messengers. Cellular NAD + levels are dynamically controlled by synthesis and degradation, and dysregulation of this balance has been associated with acute and chronic neuronal dysfunction. Recent Advances: A decline in NAD + has been observed during normal aging and since aging is the primary risk factor for many neurological disorders, NAD + metabolism has become a promising therapeutic target and prolific research field in recent years. Critical Issues: In many neurological disorders, either as a primary feature or as consequence of the pathological process, neuronal damage is accompanied by dysregulated mitochondrial homeostasis, oxidative stress, or metabolic reprogramming. Modulating NAD + availability appears to have a protective effect against such changes observed in acute neuronal damage and age-related neurological disorders. Such beneficial effects could be, at least in part, due to the activation of NAD + -dependent signaling processes. Future Directions: While in many instances the protective effect has been ascribed to the activation of sirtuins, approaches that directly test the role of sirtuins or that target the NAD + pool in a cell-type-specific manner may be able to provide further mechanistic insight. Likewise, these approaches may afford greater efficacy to strategies aimed at harnessing the therapeutic potential of NAD + -dependent signaling in neurological disorders. Antioxid. Redox Signal . 39, 1150–1166.","journal":"Antioxidants and Redox Signaling","year":2023,"id":346220,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":12,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.959,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1086583,"name":"Daniel Esteve","orcid":"0000-0002-6535-3793","position":1,"is_corresponding":false},{"id":305032,"name":"Mariana Pehar","orcid":"0000-0002-1231-4563","position":2,"is_corresponding":false},{"id":305034,"name":"Marcelo R. Vargas","orcid":"0000-0003-1039-4210","position":3,"is_corresponding":false},{"id":371154,"name":"Mariana Bresque","orcid":"0000-0002-4570-3629","position":0,"is_corresponding":true}],"reference_count":176,"raw_metadata":null,"created_at":"2026-07-19T01:11:48.317335Z","pmid":"37288742","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}